@article{211396c952b045a28ae0f197853d4fcb,
title = "Understanding deficient emotional self-regulation in adults with attention deficit hyperactivity disorder: A controlled study",
abstract = "While symptoms of deficient emotional self-regulation (DESR) such as low frustration tolerance, temper outbursts, emotional impulsivity, and mood lability are commonly associated with attention deficit hyperactivity disorder (ADHD), little is known about their nature. The main aim of this post hoc study was to examine the correlates of DESR in a large sample of adults with and without ADHD. Subjects were 206 adults with ADHD and 123 adults without ADHD from a family study of ADHD. Emotional impulsivity was operationalized using items from the Barkley Current Behavior Scale. Subjects were comprehensively assessed for psychiatric comorbidity using structured diagnostic interview methodology. We used the Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form (QLES-Q-SF) and Social Adjustment Scale-Self-report (SAS-SR) to assess quality of life and psychosocial functioning. DESR was more common among ADHD compared with non-ADHD adults, and 55 % of adults with ADHD reported extreme DESR of greater severity than 95 % of control subjects. The association of ADHD and DESR was not entirely accounted for by either current or lifetime comorbid disorders. DESR was also associated with significant functional impairment as evaluated by the QLES-Q-SF and SAS-SR, and with reduced marital status, as well as higher risk for traffic accidents and arrests. DESR adversely impacts quality of life in adults with ADHD. More work is needed to further evaluate DESR in clinical and investigational studies of subjects with ADHD.",
keywords = "Adult, Attention deficit hyperactivity disorder, Comorbidity, Emotion",
author = "Surman, {Craig B.H.} and Joseph Biederman and Thomas Spencer and Miller, {Carolyn A.} and McDermott, {Katie M.} and Faraone, {Stephen V.}",
note = "Funding Information: speaker for or on a speaker bureau or has been an Advisor or on an Advisory Board of the following sources: Alcobra, Shire Laboratories, Inc, Eli Lilly & Company, Glaxo-Smith Kline, Janssen Pharmaceutical, McNeil Pharmaceutical, Novartis Pharmaceuticals, Cephalon, Pfizer, the National Institute of Mental Health and the Department of Defense. Dr. Spencer receives research support from Royalties and Licensing fees on copyrighted ADHD scales through MGH Corporate Sponsored Research and Licensing. Dr. Spencer has a US Patent Application pending Provisional Number (61/233,686), through MGH corporate licensing, on a method to prevent stimulant abuse. In the past year, Dr. Faraone received consulting income and/or research support from Shire, Otsuka and Alcobra and research support from the National Institutes of Health (NIH). He is also on the Clinical Advisory Board for Akili Interactive Labs. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: Straight Talk About Your Child{\textquoteright}s Mental Health and Oxford University Press: Schizophrenia: The Facts. Ms. Carolyn Miller and Ms. Katie McDermott report no competing interests. Shire Pharmaceuticals provided support for this analysis. This work was supported in part by grants to S. V. Faraone from the National Institute of Health (R01MH57934). We are grateful to Dr. Russell Barkley for generously allowing us to use his questionnaire from NIMH Grant 1R01MH054509-01A2.",
year = "2013",
month = sep,
doi = "10.1007/s12402-012-0100-8",
language = "English",
volume = "5",
pages = "273--281",
journal = "ADHD Attention Deficit and Hyperactivity Disorders",
issn = "1866-6116",
publisher = "Springer-Verlag Wien",
number = "3",
}